Federal Register / Vol. 75, No. 244 / Tuesday, December 21, 2010 / Notices 80051 

1The comment must be accompanied by an 

explicit request for confidential treatment, 

including the factual and legal basis for the request, 

and must identify the specific portions of the 

comment to be withheld from the public record. 

The request will be granted or denied by the 

Continued 

between that person’s public 

responsibilities (which includes 

membership on an EPA Federal 

advisory committee) and private 

interests and activities, or the 

appearance of a lack of impartiality, as 

defined by Federal regulation. The form 

may be viewed and downloaded from 

the following URL address http:// 

www.epa.gov/sab/pdf/epaform3110– 

48.pdf. 

The approved policy under which the 

EPA SAB Office selects subcommittees 

and review panels is described in the 

following document: Overview of the 

Panel Formation Process at the 

Environmental Protection Agency 

Science Advisory Board (EPA–SAB–EC– 

02–010), which is posted on the SAB 

Web site at http://www.epa.gov/sab/pdf/ 

ec02010.pdf. 

Dated: December 14, 2010. 

Vanessa T. Vu, 

Director, EPA Science Advisory Board Staff 

Office. 

[FR Doc. 2010–32031 Filed 12–20–10; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL MARITIME COMMISSION 

Performance Review Board 

AGENCY: Federal Maritime Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given of the 

names of the members of the 

Performance Review Board. 

FOR FURTHER INFORMATION CONTACT: 

Harriette H. Charbonneau, Director of 

Human Resources, Federal Maritime 

Commission, 800 North Capitol Street, 

NW., Washington, DC 20573. 

SUPPLEMENTARY INFORMATION: Section 

4314(c) (1) through (5) of title 5, U.S.C., 

requires each agency to establish, in 

accordance with regulations prescribed 

by the Office of Personnel Management, 

one or more performance review boards. 

The board shall review and evaluate the 

initial appraisal of a senior executive’s 

performance by the supervisor, along 

with any recommendations to the 

appointing authority relative to the 

performance of the senior executive. 

Richard A. Lidinsky, Jr., 

Chairman. 

The Members of the Performance 

Review Board are: 

1. Joseph E. Brennan, Commissioner. 

2. Rebecca F. Dye, Commissioner. 

3. Michael A. Khouri, Commissioner. 

4. Clay G. Guthridge, Administrative 

Law Judge. 

5. Erin M. Wirth, Administrative Law 

Judge. 

6. Florence A. Carr, Deputy Managing 

Director. 

7. Rebecca A. Fenneman, General 

Counsel. 

8. Karen V. Gregory, Secretary. 

9. Vern W. Hill, Director, Office of 

Consumer Affairs and Dispute 

Resolution Services. 

10. Peter J. King, Director, Bureau of 

Enforcement. 

11. Sandra L. Kusumoto, Director, 

Bureau of Certification and Licensing. 

12. Ronald D. Murphy, Managing 

Director. 

13. Austin L. Schmitt, Director, 

Bureau of Trade Analysis. 

[FR Doc. 2010–32016 Filed 12–20–10; 8:45 am] 

BILLING CODE 6730–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

notices are set forth in paragraph 7 of 

the Act (12 U.S.C. 1817(j)(7)). 

The notices are available for 

immediate inspection at the Federal 

Reserve Bank indicated. The notices 

also will be available for inspection at 

the offices of the Board of Governors. 

Interested persons may express their 

views in writing to the Reserve Bank 

indicated for that notice or to the offices 

of the Board of Governors. Comments 

must be received not later than January 

7, 2011. 

A. Federal Reserve Bank of Kansas 

City (Dennis Denney, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Tribble Family Partners, L.P.; Vera 

Tribble, general partner; David Tribble, 

limited partner; all of Unionville, 

Missouri; and Diana Bennett, limited 

partner, Bethany, Missouri, to retain 

shares of Northern Missouri Bancshares, 

Inc., parent of Farmers Bank of Northern 

Missouri, National Association, both in 

Unionville, Missouri. 

Board of Governors of the Federal Reserve 

System, December 16, 2010. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2010–31990 Filed 12–20–10; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL TRADE COMMISSION 

[File No. 082 3158] 

The Dannon Company, Inc.; Analysis 

of Proposed Consent Order To Aid 

Public Comment 

AGENCY: Federal Trade Commission. 

ACTION: Proposed consent agreement. 

SUMMARY: The consent agreement in this 

matter settles alleged violations of 

federal law prohibiting unfair or 

deceptive acts or practices or unfair 

methods of competition. The attached 

Analysis To Aid Public Comment 

describes both the allegations in the 

draft complaint and the terms of the 

consent order—embodied in the consent 

agreement—that would settle these 

allegations. 

DATES: Comments must be received on 

or before January 18, 2011. 

ADDRESSES: Interested parties are 

invited to submit written comments 

electronically or in paper form. 

Comments should refer to ‘‘Dannon, File 

No. 082 3158’’ to facilitate the 

organization of comments. Please note 

that your comment—including your 

name and your state—will be placed on 

the public record of this proceeding, 

including on the publicly accessible 

FTC Web site, at http://www.ftc.gov/os/ 

publiccomments.shtm. 

Because comments will be made 

public, they should not include any 

sensitive personal information, such as 

an individual’s Social Security Number; 

date of birth; driver’s license number or 

other state identification number, or 

foreign country equivalent; passport 

number; financial account number; or 

credit or debit card number. Comments 

also should not include any sensitive 

health information, such as medical 

records or other individually 

identifiable health information. In 

addition, comments should not include 

any ‘‘[t]rade secret or any commercial or 

financial information which is obtained 

from any person and which is privileged 

or confidential * * *.,’’ as provided in 

Section 6(f) of the FTC Act, 15 U.S.C. 

46(f), and Commission Rule 4.10(a)(2), 

16 CFR 4.10(a)(2). Comments containing 

material for which confidential 

treatment is requested must be filed in 

paper form, must be clearly labeled 

‘‘Confidential,’’ and must comply with 

FTC Rule 4.9(c), 16 CFR 4.9(c).1


srobinson on DSKHWCL6B1PROD with NOTICES
80052 Federal Register / Vol. 75, No. 244 / Tuesday, December 21, 2010 / Notices 

Commission’s General Counsel, consistent with 

applicable law and the public interest. See FTC 

Rule 4.9(c), 16 CFR 4.9(c). 

Because paper mail addressed to the 

FTC is subject to delay due to 

heightened security screening, please 

consider submitting your comments in 

electronic form. Comments filed in 

electronic form should be submitted by 

using the following weblink: https:// 

ftcpublic.commentworks.com/ftc/ 

dannon and following the instructions 

on the web-based form. To ensure that 

the Commission considers an electronic 

comment, you must file it on the webbased form at the weblink: https:// 

ftcpublic.commentworks.com/ftc/ 

dannon. If this Notice appears at 

http://www.regulations.gov/search/ 

index.jsp, you may also file an 

electronic comment through that Web 

site. The Commission will consider all 

comments that regulations.gov forwards 

to it. You may also visit the FTC Web 

site at http://www.ftc.gov/ to read the 

Notice and the news release describing 

it. 

A comment filed in paper form 

should include the ‘‘Dannon, File No. 

082 3158’’ reference both in the text and 

on the envelope, and should be mailed 

or delivered to the following address: 

Federal Trade Commission, Office of the 

Secretary, Room H–135 (Annex D), 600 

Pennsylvania Avenue, NW., 

Washington, DC 20580. The FTC is 

requesting that any comment filed in 

paper form be sent by courier or 

overnight service, if possible, because 

U.S. postal mail in the Washington area 

and at the Commission is subject to 

delay due to heightened security 

precautions. 

The Federal Trade Commission Act 

(‘‘FTC Act’’) and other laws the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives, 

whether filed in paper or electronic 

form. Comments received will be 

available to the public on the FTC Web 

site, to the extent practicable, at 

http://www.ftc.gov/os/ 

publiccomments.shtm. As a matter of 

discretion, the Commission makes every 

effort to remove home contact 

information for individuals from the 

public comments it receives before 

placing those comments on the FTC 

Web site. More information, including 

routine uses permitted by the Privacy 

Act, may be found in the FTC’s privacy 

policy, at http://www.ftc.gov/ftc/ 

privacy.shtm. 

FOR FURTHER INFORMATION CONTACT: 

Richard Cleland (202–326–3088), 

Bureau of Consumer Protection, 600 

Pennsylvania Avenue, NW., 

Washington, DC 20580. 

SUPPLEMENTARY INFORMATION: Pursuant 

to section 6(f) of the Federal Trade 

Commission Act, 38 Stat. 721, 15 U.S.C. 

46(f), and § 2.34 of the Commission 

Rules of Practice, 16 CFR 2.34, notice is 

hereby given that the above-captioned 

consent agreement containing a consent 

order to cease and desist, having been 

filed with and accepted, subject to final 

approval, by the Commission, has been 

placed on the public record for a period 

of thirty (30) days. The following 

Analysis To Aid Public Comment 

describes the terms of the consent 

agreement, and the allegations in the 

complaint. An electronic copy of the 

full text of the consent agreement 

package can be obtained from the FTC 

Home Page (for December 15, 2010), on 

the World Wide Web, at http:// 

www.ftc.gov/os/actions.shtm. A paper 

copy can be obtained from the FTC 

Public Reference Room, Room 130–H, 

600 Pennsylvania Avenue, NW., 

Washington, DC 20580, either in person 

or by calling (202) 326–2222. 

Public comments are invited, and may 

be filed with the Commission in either 

paper or electronic form. All comments 

should be filed as prescribed in the 

ADDRESSES section above, and must be 

received on or before the date specified 

in the DATES section. 

Analysis of Agreement Containing 

Consent Order To Aid Public Comment 

The Federal Trade Commission 

(‘‘FTC’’ or ‘‘Commission’’) has accepted, 

subject to final approval, an agreement 

containing a consent order from The 

Dannon Company, Inc. (‘‘respondent’’). 

The proposed consent order has been 

placed on the public record for thirty 

(30) days for receipt of comments by 

interested persons. Comments received 

during this period will become part of 

the public record. After thirty (30) days, 

the Commission will again review the 

agreement and the comments received, 

and will decide whether it should 

withdraw from the agreement or make 

final the agreement’s proposed order. 

This matter involves the advertising 

and promotion of DanActive, a probiotic 

dairy drink, and Activia, a probiotic 

yogurt. According to the FTC complaint, 

respondent represented, in various 

advertisements, that drinking DanActive 

reduces the likelihood of getting a cold 

or the flu. The complaint alleges that 

these claims are unsubstantiated and 

thus violate the FTC Act. The complaint 

also alleges that respondent represented 

that clinical studies prove that drinking 

DanActive reduces the likelihood of 

getting a cold or the flu. The complaint 

alleges that these claims are false and 

thus violate the FTC Act. 

With respect to Activia, the complaint 

alleges that respondent represented, in 

various advertisements, that eating one 

serving of Activia daily relieves 

temporary irregularity and helps with 

slow intestinal transit time. The 

complaint alleges that these claims are 

unsubstantiated and thus violate the 

FTC Act. The complaint also alleges that 

respondent represented that clinical 

studies prove that eating one serving of 

Activia daily relieves temporary 

irregularity and helps with slow 

intestinal transit time. The complaint 

alleges that these claims are false and 

thus violate the FTC Act. 

The proposed consent order contains 

provisions designed to prevent 

respondent from engaging in similar 

acts or practices in the future. The order 

covers representations made in 

connection with the manufacturing, 

labeling, advertising, promotion, 

offering for sale, sale, or distribution of 

any covered product, in or affecting 

commerce. The order defines a covered 

product as: (a) Any yogurt, including 

but not limited to, Activia yogurt; (b) 

any dairy drink; and (c) any food or 

drink not covered by the foregoing that 

contains a probiotic, including, but not 

limited to, DanActive. 

Part I of the consent order is designed 

to address the complaint allegations 

concerning respondent’s allegedly 

unsubstantiated representations that 

drinking DanActive reduces the 

likelihood of getting a cold or the flu. 

Part I prohibits respondent from making 

representations that any covered 

product reduces the likelihood of 

getting a cold or the flu unless the 

representation is specifically permitted 

in labeling for such product by 

regulations promulgated by the Food 

and Drug Administration (‘‘FDA’’) 

pursuant to the Nutrition Labeling and 

Education Act of 1990 (‘‘NLEA’’). Under 

this provision, therefore, respondent 

cannot claim that a covered product 

reduces the likelihood of getting a cold 

or the flu unless the FDA has issued a 

regulation authorizing the claim based 

on a finding that there is significant 

scientific agreement among experts 

qualified by scientific training and 

experience to evaluate such claims, 

considering the totality of publicly 

available scientific evidence. As noted 

in the Commission’s Enforcement Policy 

Statement on Food Advertising, ‘‘[t]he 

Commission regards the ‘significant 

scientific agreement’ standard, as set 

forth in the NLEA and FDA’s 

regulations, to be the principal guide to 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 75, No. 244 / Tuesday, December 21, 2010 / Notices 80053 

what experts in the field of diet-disease 

relationships would consider reasonable 

substantiation for an unqualified health 

claim.’’ Enforcement Policy Statement 

on Food Advertising (1994), available at 

http://www.ftc.gov/bcp/policystmt/adfood.shtm. Thus, although the 

Enforcement Policy Statement does not 

say that the only way a food advertiser 

can adequately substantiate a disease 

risk-reduction claim is through FDA 

authorization, the consent order 

provision requiring FDA pre-approval 

before respondent makes a reduced cold 

or flu likelihood claim for its covered 

products in the future will facilitate 

compliance with and enforcement of the 

order and is reasonably related to the 

violations alleged. 

Respondent may decide to make an 

advertising claim characterizing limited 

scientific evidence supporting the 

relationship between a covered product 

and a reduced likelihood of getting a 

cold or the flu. However, if the net 

impression of that advertising is that the 

covered product reduces the likelihood 

of getting a cold or the flu, and not 

merely that there is limited scientific 

evidence supporting the claim, the 

advertisement would be covered under 

Part I. The Commission notes that its 

experience and research show that it is 

very difficult to adequately qualify a 

disease risk-reduction claim in 

advertising to indicate that the science 

supporting the claimed effect is limited. 

In other words, reasonable consumers 

may interpret an advertisement to mean 

that the product will reduce the 

likelihood of getting a cold or the flu, 

even if respondent includes language 

indicating that the science supporting 

the effect is limited in some way. 

However, if respondent possesses 

reliable empirical testing demonstrating 

that the net impression of an 

advertisement making a qualified claim 

for a covered product does not convey 

that it will reduce the likelihood of 

getting a cold or the flu, then that claim 

would be covered under Part IV of the 

order. 

Although Part I requires FDA 

approval before respondent can make 

claims that a covered product reduces 

the likelihood of getting a cold or the 

flu, the Commission does not intend 

Part I to limit respondent to using the 

precise language specified in an FDAapproved health claim. To the contrary, 

if the FDA has approved a claim that a 

covered product reduces the likelihood 

of getting a cold or the flu, respondent 

may use a variety of words and images 

to communicate that claim in its 

advertising. Conversely, regardless of 

the particular words or images used, if 

the net impression of an advertisement 

is that a covered product reduces the 

likelihood of getting a cold or the flu, 

then for the ad to comply with the 

order, the FDA must have authorized a 

health claim based on significant 

scientific agreement that such product 

provides such a benefit. 

Part II of the consent order prohibits 

respondent from making representations 

that eating one serving of Activia yogurt 

daily relieves temporary irregularity and 

helps with slow intestinal transit time 

unless the representation is nonmisleading and it conveys that eating 

three servings a day is required to obtain 

the benefit. Part II further provides, 

however, that the order does not 

prohibit respondent from representing 

that the benefit can be achieved from 

eating less than three servings a day if 

such claim is non-misleading and 

respondent possesses and relies upon 

competent and reliable scientific 

evidence that substantiates that such 

representation is true. 

For purposes of Part II, competent and 

reliable scientific evidence means at 

least two adequate and well-controlled 

human clinical studies of the product, 

or of an essentially equivalent product, 

conducted by different researchers, 

independently of each other, that 

conform to acceptable designs and 

protocols and whose results, when 

considered in light of the entire body of 

relevant and reliable scientific evidence, 

are sufficient to substantiate that the 

representation is true. For purposes of 

the order, essentially equivalent product 

means a product that contains the 

identical ingredients, except for inactive 

ingredients (e.g., inactive binders, 

flavors, preservatives, colors, fillers, 

excipients), in the same form and 

dosage, and with the same route of 

administration (e.g., orally, 

sublingually), as the covered product; 

provided that the covered product may 

contain additional ingredients or other 

differences in formulation to affect taste, 

texture, or nutritional value (so long as 

the other differences do not change the 

form of the product or involve the 

ingredients from which the functional 

benefit is derived), if reliable scientific 

evidence generally accepted by experts 

in the field demonstrates that the 

amount of additional ingredients, 

combination of additional ingredients, 

and any other differences in formulation 

are unlikely to impede or inhibit the 

effectiveness of the ingredients in the 

essentially equivalent product. 

Part III of the consent order prohibits 

respondent from making representations 

that any covered product other than 

Activia yogurt relieves temporary 

irregularity and helps with slow 

intestinal transit time unless the 

representation is non-misleading and 

respondent possesses and relies upon 

competent and reliable scientific 

evidence that substantiates that such 

representation is true. For purposes of 

Part III, competent and reliable 

scientific evidence means at least two 

adequate and well-controlled human 

clinical studies of the product, or of an 

essentially equivalent product, 

conducted by different researchers, 

independently of each other, that 

conform to acceptable designs and 

protocols and whose results, when 

considered in light of the entire body of 

relevant and reliable scientific evidence, 

are sufficient to substantiate that the 

representation is true. 

Part IV of the consent order prohibits 

respondent from making 

representations, other than 

representations covered under Parts I 

through III, about the health benefits, 

performance, or efficacy of any covered 

product, unless the representation is 

non-misleading, and, at the time of 

making such representation, respondent 

possesses and relies upon competent 

and reliable scientific evidence that is 

sufficient in quality and quantity based 

on standards generally accepted in the 

relevant scientific fields, when 

considered in light of the entire body of 

relevant and reliable scientific evidence, 

to substantiate that the representation is 

true. For purposes of Part IV, competent 

and reliable scientific evidence means 

tests, analyses, research, studies, or 

other evidence that have been 

conducted and evaluated in an objective 

manner by qualified persons, that are 

generally accepted in the profession to 

yield accurate and reliable results. 

Part V of the consent order prohibits 

respondent from misrepresenting the 

existence, contents, validity, results, 

conclusions, or interpretations of any 

test, study, or research, including but 

not limited to any misrepresentation 

that a covered product is clinically 

proven (1) to reduce the likelihood of 

getting a cold or flu, or (2) to relieve 

temporary irregularity or help with slow 

intestinal transit time. 

Part VI of the consent order provides 

that nothing in the order shall prohibit 

respondent from making any 

representation for any product that is 

specifically permitted in labeling for 

such product by regulations 

promulgated by the FDA pursuant to the 

NLEA. 

Parts VII, VIII, IX, and X of the 

consent order require respondent to 

keep copies of relevant advertisements 

and materials substantiating claims 

made in the advertisements; to provide 

copies of the order to its personnel; to 

notify the Commission of changes in 


srobinson on DSKHWCL6B1PROD with NOTICES
80054 Federal Register / Vol. 75, No. 244 / Tuesday, December 21, 2010 / Notices 

corporate structure that might affect 

compliance obligations under the order; 

and to file compliance reports with the 

Commission. Part XI provides that the 

order will terminate after twenty (20) 

years, with certain exceptions. 

The purpose of this analysis is to 

facilitate public comment on the 

proposed order, and it is not intended 

to constitute an official interpretation of 

the agreement and proposed order or to 

modify their terms in any way. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 2010–31936 Filed 12–20–10; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Input for a Strategic Plan for Federal 

Youth Policy 

AGENCY: Office of the Assistant 

Secretary for Planning and Evaluation, 

DHHS. 

ACTION: Notice of request for public 

comments. 

SUMMARY: The U.S. Department of 

Health and Human Services, in its role 

as the Chair of the Interagency Working 

Group on Youth Programs requests 

public comments to inform the 

development of a strategic plan for 

Federal youth policy. 

DATES: Comments must be received on 

or before January 20, 2011. 

ADDRESSES: You may submit comments 

electronically through the 

FindYouthInfo.gov Web site via http:// 

www.findyouthinfo.gov/ 

provideinput.aspx. You may e-mail 

them to FindYouthInfo@air.org. You 

may mail them to Sarah Potter, Office of 

the Assistant Secretary for Planning and 

Evaluation, U.S. Department of Health 

and Human Services, 200 Independence 

Avenue, SW., Room 404E, Washington, 

DC 20201. To ensure proper handling, 

in the lower left hand corner of the 

envelope and in your correspondence 

clearly reference ‘‘Strategic Plan for 

Federal Youth Policy.’’ 

FOR FURTHER INFORMATION CONTACT: Visit 

the Web site for the Interagency 

Working Group on Youth Programs at 

http://www.FindYouthInfo.gov; call 

FindYouthInfo.gov helpline at 1–877– 

231–7843 (this is a toll-free number); or 

e-mail your inquiry to 

FindYouthInfo@air.org. 

SUPPLEMENTARY INFORMATION: 

I. Overview of the Interagency Working 

Group on Youth Programs and 

FindYouthInfo.gov 

The Interagency Working Group on 

Youth Programs is comprised of staff 

from twelve Federal agencies that 

support programs and services that 

focus on youth: the U.S. Department of 

Agriculture; U.S. Department of 

Commerce; U.S. Department of Defense; 

U.S. Department of Education; U.S. 

Department of Health and Human 

Services (Chair); U.S. Department of 

Housing and Urban Development; U.S. 

Department of Justice (Vice-Chair); U.S. 

Department of Labor; U.S. Department 

of the Interior; U.S. Department of 

Transportation; Corporation for National 

and Community Service; and Office of 

National Drug Control Policy. 

The Working Group seeks to promote 

achievement of positive results for atrisk youth through the following 

activities: 

• Promoting enhanced collaboration at the 

Federal, State, and local levels, including 

with faith-based and other community 

organizations, as well as among families, 

schools and communities, in order to 

leverage existing resources and improve 

outcomes; 

• Disseminating information about critical 

resources, including evidence-based 

programs, to assist interested citizens and 

decision-makers, particularly at the 

community level, to plan, implement, and 

participate in effective strategies for at-risk 

youth; 

• Developing an overarching strategic plan 

for Federal youth policy, as well as 

recommendations for improving the 

coordination, effectiveness and efficiency of 

youth programs, using input from 

community stakeholders, including youth; 

and 

• Producing a Federal Web site, 

FindYouthInfo.gov, to promote effective 

community-based efforts to reduce the factors 

that put youth at risk and to provide highquality services to at-risk youth. 

II. Background on the Strategic Plan for 

Federal Youth Policy 

On March 11, 2009, the Congress 

passed the Omnibus Appropriations 

Act, 2009 (Pub. L. 111–8). The House 

Appropriations Committee Print, 

Division F—Departments of Labor, 

Health and Human Services, and 

Education, and Related Agencies 

Appropriations directed the Interagency 

Working Group on Youth Programs to 

solicit input from young people, State 

children’s cabinet directors, and nonprofit organizations on youth programs 

and policies; develop an overarching 

strategic plan for Federal youth policy; 

and prepare recommendations to 

improve the coordination, effectiveness, 

and efficiency of programs affecting 

youth. 

The Interagency Working Group on 

Youth Programs developed a framework 

to guide development of the strategic 

plan for Federal youth policy. This 

framework is available online at http:// 

www.findyouthinfo.gov/ 

provideinput.aspx. The framework 

illustrates how programs and 

practices—such as (1) Physical and 

mental health and wellness; (2) 

education; (3) juvenile justice 

intervention; (4) enrichment 

opportunities; (5) safety; (6) service 

learning; (7) employment; and (8) 

housing—pertain to youth up to age 24. 

The framework acknowledges that 

programs and policies are designed to 

meet the diverse needs of youth, 

including the general youth population, 

youth involved in systems, and special 

youth populations. The Working Group 

is focusing on youth across several 

developmental stages, including (1) 

early adolescence (ages under 14); (2) 

middle adolescence (ages 15–17); and 

(3) late adolescence/early adulthood 

(ages 18–24). The Working Group is 

focused on three overarching outcomes 

for youth through this framework: (1) 

basic needs: health, safety, and 

wellness; (2) school, family, and 

community engagement and 

connections; and (3) education, training, 

employment, transitions, and readiness 

for careers and adulthood. 

III. Guiding Questions for Commenters 

The Interagency Working Group on 

Youth Programs has identified a number 

of questions to focus on, and the 

Working Group is particularly interested 

in receiving comments addressing some 

or all of these questions. 

(a) What is the single most important thing 

youth need to be successful? 

(b) What programs really make a difference 

in the lives of youth? How do you know this? 

(c) What are the barriers to collaborating to 

improving youth outcomes and how can 

these barriers be removed? 

(d) What can Federal agencies do to assist? 

What are your ideas for Federal policy to 

improve the coordination, effectiveness, and 

efficiency of programs affecting youth? 

(e) How can youth be engaged in these 

efforts? 

Authority: Division F, Pub. L. 111–8; E.O. 

13459, 73 FR 8003, February 12, 2008. 

Dated: December 10, 2010. 

Sherry Glied, 

Assistant Secretary for Planning and 

Evaluation. 

[FR Doc. 2010–31975 Filed 12–20–10; 8:45 am] 

BILLING CODE 4154–05–P 


srobinson on DSKHWCL6B1PROD with NOTICES